{
    "2021-09-17": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)",
                "features": {
                    "keywords": [
                        "Novartis",
                        "alpelisib",
                        "clinical benefit",
                        "PIK3CA-Related Overgrowth Spectrum",
                        "real-world study"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Prostate Cancer Therapy",
                        "Improved Quality Of Life"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}